Marjorie Sennett
Known title: DirectorCIK: 0001616123
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Cognex Faces Mixed Sentiment Amid AI and Robotics News. Recent commentary highlights Cognex's potential in AI and robotics, but notes that near-term upside may be limited. Some analysts suggest waiting for a better entry point, while others flag warning signs despite the company's selection as a Lidar partner for NVIDIA. The stock trades with a high P/E ratio, reflecting high growth expectations.
Transaction History
| VC | ▲ Buy | Option Exercise | 1,219 | — | 7/17/2026 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 2,913 | $0 | 2/21/2026 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 8,324 | $0 | 2/18/2026 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 2,134 | $0 | 2/22/2025 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 1,747 | $0 | 2/21/2025 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 6,973 | $0 | 2/20/2025 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 272 | $0 | 11/8/2024 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 1,281 | $0 | 2/22/2024 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 1,166 | $0 | 2/21/2024 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 163 | $0 | 11/8/2023 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 854 | $0 | 2/22/2023 | View on chart |
| CGNX | ▲ Buy | Option Exercise | 109 | $0 | 11/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Visteon faces price target cuts from Barclays, UBS, and Goldman Sachs
Three major banks recently lowered their price targets for Visteon, with Barclays cutting to $125, UBS to $107, and Goldman Sachs to $104. Despite these reductions, all three firms maintained their positive ratings on the stock. The moves come as the stock trades near its 52-week low, reflecting broader caution in the automotive supplier sector.
Visteon faces price target cuts from Barclays, UBS, and Goldman Sachs. Three major banks recently lowered their price targets for Visteon, with Barclays cutting to $125, UBS to $107, and Goldman Sachs to $104. Despite these reductions, all three firms maintained their positive ratings on the stock. The moves come as the stock trades near its 52-week low, reflecting broader caution in the automotive supplier sector.